Sexual adverse effects and erectile dysfunction during buprenorphine/naloxone combination treatment for opioid use disorders

Neuropsychiatric Disease and TreatmentBestepe EE, Tunali N, Sarıdoğan GE., et al. | November 13, 2020

Advertisement

In this study, sexual dysfunction with buprenorphine/naloxone (bup/nal) treatment in a Turkish alcohol and substance use disorder treatment center sample were evaluated. Researchers included 100 individuals continuing sublingual bup/nal combination and 35 control. Individuals were assessed via the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) for sexual dysfunction and for erectile dysfunction (ED) with the International Index of Erectile Function-5 (IIEF-5) as a comparison. In comparison with non-treatment controls, the bup/nal combination leads to a higher degree of ED severity. It was shown that in patients with opioid use disorder, noncommunication appears to play a role as a risk factor for ED. The results considered that effective communication can be a key factor for sexual assertivity and disclosing the sexual adverse impacts to the clinicians as well as staying in the treatment.

Read the full article on Neuropsychiatric Disease and Treatment

Advertisement